Objectives This study sought to report the long-term outcomes after drug-eluting stent (DES) implantation in saphenous vein graft (SVG) lesions in the SOS (Stenting of Saphenous Vein Grafts) trial.
Whether drug-eluting stents (DES) provide superior clinical outcomes compared with bare-metal stents (BMS) when used in saphenous vein graft (SVG) lesions remains controversial. Although 7 angiographic studies have all reported consistent reduction in in-stent late loss with DES than BMS in SVGs, the impact of DES on clinical outcomes has varied: approximately one-half of the published comparative studies suggested benefit with DES and one-half revealed no difference between DES and BMS (1). Only 2 randomized-controlled trials of DES versus BMS have been published to date. The RRISC (Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent) trial compared a sirolimus-eluting stent (Cypher, Cordis, Warren, New Jersey) with a BMS of similar design (2, 3) . The SOS (Stenting of Saphenous Vein Grafts) trial compared a paclitaxel-eluting stent (PES) (Taxus, Boston Scientific, Natick, Massachusetts) to a similar BMS (4 -6) . In the RRISC trial, an initial benefit seen at 6 months (2) was no longer present at a median of 32 months of follow-up; moreover, the DES group had higher mortality (3) . In the SOS trial, an angiographic and clinical benefit was seen with PES during a median follow-up of 18 months. Here, we report the long-term outcomes of patients enrolled in the SOS trial.
Methods
The primary results of the SOS trial have been published (4) . The SOS trial was a randomized, controlled, singleblinded, multicenter trial designed to test the hypothesis that implantation of PES in SVG lesions would result in lower 12-month angiographic restenosis rate compared with the rates for a similar BMS (Express 2 , Boston Scientific). Repeat angiography was performed in 83% of patients. Patients were asked to return for repeat coronary angiography 12 months after stent implantation and were contacted by phone until 24 months after enrollment to determine whether any late cardiovascular events had occurred. The SOS trial was approved by each participating site's Institutional Review Board, and all patients provided written informed consent. Due to concerns about the long-term outcomes after DES implantation in SVGs, Institutional Review Board approval was obtained to contact the patients to determine longer-term outcomes in 2010. Follow-up was available for all patients except 1.
In the present analysis, we examined the incidence of several clinical end points (death, target lesion revascularization, target and nontarget vessel revascularization, target vessel failure, device-oriented composite end point, major adverse cardiac events, and stent thrombosis) during the follow-up period. Myocardial infarctions (MIs) included in the present analysis were those occurring during follow-up, without including periprocedural cardiac biomarker increases. Target vessel failure was defined as the composite end point of cardiac death, MI, and target vessel revascularization. A composite end point of cardiac death, MI attributed to the target vessel, and target lesion revascularization was also evaluated (device-oriented composite end point, as suggested by Cutlip et al. [7] ). For this analysis, if an adverse event could not unequivocally be attributed to a nontarget vessel, the event was considered to represent target-vessel failure. We also assessed the incidence of major adverse cardiac events defined as the composite of any death, any MI, or any coronary revascularization (similar to the patient-oriented composite end point suggested by Cutlip et al. [7] ).
The incidence of these end points was calculated using the Kaplan-Meier method, and the differences between the 2 study groups were compared using the log-rank test. Cox proportional hazards methods were used to calculate the hazard ratios for the PES versus BMS groups for each of the end points. All analyses were performed on an intentionto-treat principle using JMP 8 (SAS Institute, Cary, North Carolina) and SPSS (SPSS Inc., Chicago, Illinois). A 2-sided p value Ͻ0.05 was considered statistically significant.
Results
Patient characteristics. Between 2005 and 2007, 80 patients were enrolled in the SOS trial and were randomized to a BMS (n ϭ 39) or a PES (n ϭ 41). Mean age was 67 Ϯ 9 years and all patients were men. The 2 study groups had similar baseline clinical and procedural characteristics ( 
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Long-Term Outcomes of the SOS Trial indications for angiography and stenting included acute coronary syndrome in 60% and stable angina in 31%. The mean SVG age was 12 Ϯ 6 years. The territory supplied by the target SVGs was the left anterior descending artery in 28%, circumflex in 38%, and right coronary artery in 34%. An embolic protection device was used in 54% of the lesions. Procedural success was achieved in 77 patients (96%). Long-term outcomes. The clinical outcomes during a median follow-up of 35 months are presented in Figure 1 and Table 2 .
Overall, 52 of 80 patients who participated in the SOS trial experienced at least 1 major adverse cardiac event during long-term follow-up: 30 of 39 BMS patients and 22 of 41 PES patients. The major adverse cardiac events were related to the target SVG in 77% of BMS versus 45% of PES patients and were not related to the target SVG in 7% of BMS versus 41% of PES patients; the relationship to the target SVG could not be determined in 17% of the BMS versus 14% of the PES patients (p ϭ 0.01).
Five patients in the BMS and 10 in the PES group died during follow-up (log rank, p ϭ 0.19) (Fig. 1) . The cause of death in the BMS group was cardiac arrest in 1 patient, sudden in 2 patients, and unknown in 2 patients. In the PES group, death was due to MI in 1 patient, end-stage heart failure in 1 patient, unknown cause in 1 patient, and noncardiac causes in the remaining 7 patients (lung cancer in 4 patients, small bowel obstruction, multiple strokes and pneumonia, and chronic obstructive pulmonary disease, each in 1 patient).
A total of 25 patients (18 in the BMS and 7 in the PES group) experienced a MI during follow-up. In the BMS group, the MI was related to the target SVG in 9 of 18 patients (due to in-stent restenosis in 4 patients, stent thrombosis in 4 patients, and progression of intermediate BMS ϭ bare-metal stent(s); PCI ϭ percutaneous coronary intervention; PES ϭ paclitaxel-eluting stent(s); SVG ϭ saphenous vein graft. There was no difference in all-cause mortality between the study groups (A). The incidence of myocardial infarction (B), target lesion revascularization (C), and target vessel failure (D) (composite end point of cardiac death, myocardial infarction, and target vessel revascularization) was significantly lower in the paclitaxeleluting stent (PES) group than the bare-metal stent (BMS) group. Values are n (%), unless otherwise specified.
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ARC ϭ Academic Research Consortium; CI ϭ confidence interval; SOS ϭ Stenting of Saphenous Vein Grafts; other abbreviations as in Table 1 .
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Long-Term Outcomes of the SOS Trial lesion in 1 patient), was not related to the target SVG in 4 patients, or its relationship to the target SVG could not be determined in 5 patients. In the PES group, the MI was related to the target SVG in 3 of 7 patients (due to in-stent restenosis in 2 patients, and progression of an intermediate lesion in 1 patient), was not related to the target SVG in 3 patients, or its relationship to the target SVG could not be determined in 1 patient. The type of MI was non-STsegment elevation in 21 patients (15 in the BMS and 6 in the PES group), ST-segment evaluation in 1 patient (in the BMS group), or unknown in 3 patients. The incidence of target lesion and target vessel revascularization was significantly lower in the PES group (Table 1). Stroke occurred in 1 patient (in the PES group) who subsequently died. Use of clopidogrel was similar in the BMS and PES groups at 1 year (73% vs. 84%), 2 years (67% vs. 50%), and 3 years (55% vs. 58%) after enrollment.
Discussion
This extended analysis of the SOS trial suggests that placement of a PES in SVG lesions continued to provide benefit during a median follow-up period of 35 months compared with BMS.
The role of DES in SVG remains controversial. Five metaanalyses (8 -12) and 1 systematic review (1) comparing DES with BMS in SVG lesions have recently been published. All showed reduction in target vessel revascularization with DES. One meta-analysis also revealed reduction in MI with DES (8), and 2 suggested reduction in mortality (10,11) with DES. However, the results of these meta-analyses and systematic reviews were driven by the retrospective, uncontrolled studies that provided most of the analyzed data. As a result, the long-term outcomes presented in this analysis of the randomized SOS trial provide an important addition to the literature. Long-term follow-up is particularly important because of the high risk of intermediate SVG lesion progression (13) that could cancel out some of the early reduction in target vessel revascularization provided by DES.
Whether DES implantation in SVGs provides long-term benefit has also been controversial. The results of 17 published studies reporting Ն12-month clinical outcomes after DES versus BMS implantation in SVGs are summarized in Table 3 (2-4,14-28). Only 5 of 14 retrospective studies (14, 19, 21, 26, 28) reported a reduction in target vessel revascularization with DES implantation. However, similar to the meta-analyses, a major limitation is the retrospective nature of most long-term outcome studies. The prospective and randomized RRISC trial provides the best quality long-term comparative analysis to date (3, 29) , in which mortality at a median follow-up of 32 months, was higher in the sirolimus-eluting stent group (29% DES ϭ drug-eluting stent(s); MI ϭ myocardial infarction; NR ϭ not reported; NS ϭ not significant; SES ϭ sirolimus-eluting stent(s); TVR ϭ target vessel revascularization; other abbreviations as in Tables 1 and 2 .
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vs. 0%, p ϭ 0.001) and there was no reduction with DES in the incidence of target vessel revascularization. Several explanations for the different results observed in the SOS and RRISC trials could be proposed. First, different DES were used: a sirolimus-eluting stent was used in RRISC versus a PES in SOS. Sirolimus-eluting stent did not show benefit in a large prospective cohort study (30) (36, 37) (11% per year in RRISC compared with 5% to 7% in other studies, including SOS); moreover, the BMS arm of RRISC surprisingly had no deaths during 2.7 years. However, most deaths in the DES arm of RRISC were not related to the study SVG: 3 of 11 deaths were noncardiac, 3 of 11 were cardiac but proven to not be related to the study SVG, 3 were sudden deaths and only 2 were confirmed to be related to the study SVG (1 in-stent restenosis requiring redo coronary arterial bypass graft surgery in 1 patient and 1 perioperative stent thrombosis 14.5 months after implantation after antiplatelet therapy was discontinued before knee surgery) (3) . Similarly, in the SOS trial, 7 of 10 deaths in the PES arm were noncardiac, highlighting the high overall risk and multiple comorbidities of patients who need SVG stenting. Third, there were significant differences between the 2 study populations: patients enrolled in RRISC were older (mean age 73 years vs. 67 years in SOS), less likely to have diabetes mellitus (15% vs. 44% in SOS), and received shorter duration of mandatory antiplatelet therapy (12 months in SOS vs. 2 months in RRISC). Moreover, in the SOS trial, more major adverse cardiac events were related to the target SVG in the BMS than the PES group (77% vs. 45%), suggesting that the benefit observed with PES was likely related to improved outcomes in the target SVG. Although DES are used in most SVG interventions in the U.S. (38) , there remains an unmet need for large, prospective, randomized-controlled trials to better delineate both the shortand long-term outcomes after DES implantation. Three such trials are ongoing: 1) the ISAR-CABG (Prospective, Ran- (1) . These studies, once completed, will provide a significantly improved understanding of the role of DES in SVGs. Study limitations. First, this was a non-pre-specified, post hoc analysis of the SOS trial, and the results should be viewed as hypothesis-generating. Second, all study patients were men, and even though sex differences are unlikely to contribute to the findings of this study, extrapolation of the results to women should be done with caution. Third, due to the relatively small sample size, it is subject to both type I and type II statistical error, although the study findings were consistent between the early and long-term follow-up periods.
Conclusions
In the prospective, randomized SOS trial, implantation of PES, when compared with BMS, was associated with improved long-term clinical outcomes, suggesting that PES may provide significant benefit in this high-risk patient population. 
